Last $87.48 USD
Change Today +1.90 / 2.22%
Volume 121.7K
ICUI On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

icu medical inc (ICUI) Snapshot

Open
$85.96
Previous Close
$85.58
Day High
$87.79
Day Low
$84.72
52 Week High
01/20/15 - $88.00
52 Week Low
05/5/14 - $54.00
Market Cap
1.3B
Average Volume 10 Days
124.1K
EPS TTM
$2.25
Shares Outstanding
15.4M
EX-Date
--
P/E TM
39.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for ICU MEDICAL INC (ICUI)

icu medical inc (ICUI) Related Businessweek News

No Related Businessweek News Found

icu medical inc (ICUI) Details

ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy, oncology, and critical care applications. It operates in three segments: Infusion Therapy, Critical Care, and Oncology. The company’s product line includes needlefree infusion connectors, custom infusion systems, catheters and hemodynamic monitoring systems, closed system transfer devices, and automated compounders for handling hazardous drugs. Its products enhance patient outcomes by preventing bloodstream infections, and protecting healthcare workers and patients from exposure to infectious diseases or hazardous drugs. The company offers I.V. therapy lines consisting of a tube running from a bottle or plastic bag containing an I.V. solution to a catheter inserted in a patient’s vein for use in hospitals and ambulatory clinics; and Clave product, a needlefree infusion connection device, which is used with conventional peripheral or central vascular access systems for venous and arterial applications. It also provides critical care products that monitor vital signs and specific physiological functions of key organ systems, including disposable pressure-sensing devices, blood sampling systems, minimally invasive monitoring sensors, catheters, and angiography kits for various purposes. In addition, the company provides a line of oncology products, including ChemoLock and ChemoClave closed system transfer device and components, including Genie closed vial access device and Spiros closed male luer; custom preparation and administration sets and accessories; and Diana hazardous drug compounding system. Further, it offers Tego needlefree hemodialysis connectors and Lopez enteral valves. ICU Medical, Inc. sells its products to medical product manufacturers, independent distributors, and directly to end users. The company was founded in 1984 and is headquartered in San Clemente, California.

2,269 Employees
Last Reported Date: 02/21/14
Founded in 1984

icu medical inc (ICUI) Top Compensated Officers

Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $406.6K
Vice President of Operations
Total Annual Compensation: $399.4K
Vice President of Product Development
Total Annual Compensation: $315.0K
Compensation as of Fiscal Year 2013.

icu medical inc (ICUI) Key Developments

ICU Medical, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 02:00 PM

ICU Medical, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 02:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Vivek Jain, Chairman and Chief Executive Officer.

ICU Medical, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 01:00 PM

ICU Medical, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 01:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

ICU Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

ICU Medical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's net sales were $77,329,000 against $82,709,000 a year ago. Total revenue was $77,457,000 against $82,815,000 a year ago. Income from operations was $8,409,000 against $15,416,000 a year ago. Income before income taxes was $8,564,000 against $15,606,000 a year ago. Net income was $6,428,000 or $0.42 diluted per share against $11,034,000 or $0.72 diluted per share a year ago. Adjusted EBITDA was $18,911,000 against $22,560,000 a year ago. Adjusted diluted earnings per share were $0.66 against $0.84 a year ago. This decline in adjusted EBITDA was primarily due to lower sales and increased R&D expenditures. The decrease in adjusted diluted earnings per share was primarily due to lower revenue, higher noncash-based stock compensation expense and the increased R&D, was slightly offset by lower tax rate. For the nine months, the company's net sales were $228,997,000 against $235,419,000 a year ago. Total revenue was $229,364,000 against $235,775,000 a year ago. Income from operations was $26,984,000 against $38,391,000 a year ago. Income before income taxes was $27,556,000 against $38,961,000 a year ago. Net income was $18,963,000 or $1.22 diluted per share against $27,086,000 or $1.79 diluted per share a year ago. Net cash provided by operating activities was $48,347,000 against $42,244,000 a year ago. Purchases of property and equipment was $14,924,000 against $15,223,000 a year ago. Intangible asset additions was $709,000 against $839,000 a year ago. Adjusted EBITDA was $52,028,000 against $58,886,000 a year ago. Adjusted diluted earnings per share were $1.71 against $2.11 a year ago. For the year 2014, the company now expects revenue to be in the range of $304 million to $307 million, compared to the previous range of $285 million to $300 million. GAAP diluted earnings per share increased to a range of $1.62 to $1.70 compared to the previous range of $1.30 to $1.45. Adjusted diluted earnings per share increased to a range of $2.25 to $2.33 compared to the previous range of $1.95 to $2.15, and adjusted EBITDA is increased to a range of $69 million to $71 million compared to the previous range of $63 million to $68 million. GAAP net income to be $25,094,000 to $26,363,000 a year ago. Depreciation and amortization expense to be $19,640,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICUI:US $87.48 USD +1.90

ICUI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $57.57 USD +0.41
Exactech Inc $22.37 USD +0.13
RTI Surgical Inc $4.94 USD +0.23
Tornier NV $24.88 USD +0.18
Wright Medical Group Inc $25.51 USD +0.10
View Industry Companies
 

Industry Analysis

ICUI

Industry Average

Valuation ICUI Industry Range
Price/Earnings 41.2x
Price/Sales 4.3x
Price/Book 2.7x
Price/Cash Flow 40.7x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICU MEDICAL INC, please visit www.icumed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.